E-LIB Suche - Ergebnisse für: Casneuf, T.

1

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

van de Donk, N. ; Cortes-Selva, D. ; Casneuf, T....
HemaSphere. 7 (2023) S2 - p. 28-29 , 2023

Link: https://doi.org/10.1097/..

2

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT..:

Köse, M. C. ; Bergiers, I. ; Malfait, M....
HemaSphere. 6 (2022) - p. 71-72 , 2022

Link: https://doi.org/10.1097/..

3

DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VS LENAL..:

Bahlis, N.J. ; Moreau, P. ; Nahi, H....
Hematological Oncology. 35 (2017) S2 - p. 389-389 , 2017

Link: https://doi.org/10.1002/..

4

DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE (DVD) VS BORTEZOM..:

Lentzsch, S. ; Weisel, K. ; Mateos, M.V....
Hematological Oncology. 35 (2017) S2 - p. 388-389 , 2017

Link: https://doi.org/10.1002/..

5

P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CE..:

van de Donk, N ; Cortes-Selva, D ; Casneuf, T...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171470/. , 2023

Link: http://www.ncbi.nlm.nih...

6

Genomic Profiling of Smoldering Multiple Myeloma Identifies..:

Bustoros, M ; Sklavenitis-Pistofidis, R ; Park, J...
https://discovery.ucl.ac.uk/id/eprint/10101951/3/Yong_SMM%20manuscript_JCO_revised_FINAL.pdf. , 2020

Link: https://discovery.ucl.ac..

7

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel K ; Spencer A ; Lentzsch S...
info:eu-repo/semantics/altIdentifier/wos/WOS:000566236600001. , 2020

Link: https://hdl.handle.net/1..

8

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel, K ; Spencer, A ; Lentzsch, S...
issn:1756-8722. , 2020

Link: http://hdl.handle.net/11..

9

Daratumumab, lenalidomide, and dexamethasone in relapsed/re..:

Kaufman, JL ; Dimopoulos, MA ; White, D...
issn:2044-5385. , 2020

Link: http://hdl.handle.net/11..

10

Daratumumab, bortezomib, and dexamethasone in relapsed or r..:

Weisel, K ; Spencer, A ; Lentzsch, S...
Weisel , K , Spencer , A , Lentzsch , S , Avet-Loiseau , H , Mark , T M , Spicka , I , Masszi , T , Lauri , B , Levin , M-D , Bosi , A , Hungria , V , Cavo , M , Lee , JJ , Nooka , A , Quach , H , Munder , M , Lee , C , Barreto , W , Corradini , P , Min , CK , Chanan-Khan , AA , Horvath , N , Capra , M , Beksac , M , Ovilla , R , Jo , J C , Shin , HJ , Sonneveld , P , Casneuf , T , Deangelis , N , Amin , H , Ukropec , J , Kobos , R & Mateos , MV 2020 , ' Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk ' , Journal of Hematology and Oncology , vol. 13 , no. 1 , 115 . https://doi.org/10.1186/s13045-020-00948-5. , 2020

Link: https://pure.eur.nl/en/p..

11